Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: http://www.shire.com.
THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-
looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be
materially affected. The risks and uncertainties include, but are not
limited to, risks associated with: the inherent uncertainty of
pharmaceutical research, product development, manufacturing and
commercialization; the impact of competitive products, including, but not
limited to the impact of those on Shire's Attention Deficit and
Hyperactivity Disorder ("ADHD") franchise; patents, including but not
limited to, legal challenges relating to Shire's ADHD franchise; government
regulation and approval, including but not limited to the expected product
approval date of INTUNIV(TM) (guanfacine) extended release (ADHD); Shire's
ability to secure new products for commercialization and/or development;
Shire's ability to benefit from its acquisition of New River
Pharmaceuticals Inc.; the s
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved